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H I G H L I G H T S
• Short-term psychodynamic psychotherapy (STPP) is a treatment for depression.• Adding STPP to antidepressants results in lower depressive symptom levels.• This effect is small at post-treatment and moderate at follow-up.• This effect can be related to STPP's specific treatment components.








Individual participant data meta-analysis
A B S T R A C T
Purpose: We examined the efficacy of adding short-term psychodynamic psychotherapy (STPP) to anti-
depressants in the treatment of depression by means of a systematic review and meta-analysis of individual
participant data, which is currently considered the most reliable method for evidence synthesis.
Results: A thorough systematic literature search resulted in 7 studies comparing combined treatment of anti-
depressants and STPP versus antidepressant mono-therapy (n = 3) or versus antidepressants and brief sup-
portive psychotherapy (n = 4). Individual participant data were obtained for all these studies and totaled 482
participants. Across the total sample of studies, combined treatment of antidepressants and STPP was found
significantly more efficacious in terms of depressive symptom levels at both post-treatment (Cohen's d = 0.26,
SE = 0.10, p= .01) and follow-up (d= 0.50, SE = 0.10, p < .001). This effect was most apparent at follow-up
and in studies examining STPP's specific treatment efficacy. Effects were still apparent in analyses that controlled
for risk of bias and STPP quality in the primary studies.
Conclusions: These findings support the evidence-base of adding STPP to antidepressants in the treatment of
depression. However, further studies are needed, particularly assessing outcome measures other than depression
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and cost-effectiveness, as well as examining the relative merits of STPP versus other psychotherapies as added to
antidepressants.
1. Introduction
Depression is a highly prevalent and potentially disabling disorder
associated with major personal and societal costs (Kessler, 2012). Af-
fecting more than 300 million people worldwide, depression is ranked
as the single largest contributor to global disability by the World Health
Organization (2017). Given the tremendous burden of disease, there is a
great need for effective and efficient treatments for depression. Anti-
depressant medications and different psychological therapies constitute
the predominant treatments for depressive disorders (Marcus & Olfson,
2010). Concerning psychological treatments, there is a clinical tradition
of short-term psychodynamic psychotherapies (STPPs) being used to
treat depression. STPP is an empirically supported treatment for de-
pression (Driessen et al., 2015).
Findings from ‘conventional’ meta-analyses suggest that combined
treatment of antidepressant medication and psychotherapy in general is
more efficacious than antidepressant mono-therapy in terms of de-
pressive symptom reduction (Cuijpers et al., 2014; Karyotaki et al.,
2016) and a review concludes that this might also be the case for STPP
specifically (Fonagy, 2015). However, conventional meta-analyses,
which are based on results extracted from published trial reports, are
limited as they depend on the quality of the information in publications
in which treatment effects can be overestimated. Therefore, their results
can be biased (Stewart & Parmar, 1993).
Alternatively, individual participant data meta-analysis is a tech-
nique to examine treatment effects by combining participant-level data
of multiple trials. Individual participant data meta-analysis uses the
same basic approach as any other well-conducted systematic review
and meta-analysis. However, it involves collection of the original data
from as many of the relevant trials worldwide as can be accessed.
Individual participant data meta-analysis has several advantages over
conventional meta-analysis, including the possibility to 1) account for
missing data at the individual participant level, so that for instance
intent-to-treat analyses can be conducted even though the original
study reported completers-only analyses, 2) use the same statistical
methods for imputing missing data and for conducting statistical ana-
lyses, thereby facilitating standardization across studies, 3) standardize
outcomes across studies, for instance by using equal cut-off points on a
depression outcome measure when the primary studies used different
cut-offs, and 4) verify the results presented in the original studies, also
by means of more sophisticated statistical techniques that were not
available at time of publication in the case of older studies (Riley,
Lambert, & Abo-Zaid, 2010). For these reasons, individual participant
data meta-analysis provides the least biased and most reliable means of
evidence synthesis and is considered the ‘gold standard’ in this regard
(Stewart & Parmar, 1993).
To the best of our knowledge, to date, only one individual partici-
pant data meta-analysis has examined the efficacy of adding psy-
chotherapy to antidepressants in the treatment of depression (Furukawa
et al., 2018). This network meta-analysis specifically focused on the
Cognitive-Behavioural Analysis System of Psychotherapy (CBASP) for
persistent depression. It included two studies comparing combined
treatment of antidepressants and CBASP versus antidepressant mono-
therapy and reported a mean difference in depression severity at
12 weeks of 2.6 (1.6 to 4.3) Hamilton Depression Rating Scale (HAMD)
points, favoring combined treatment.
We, therefore, conducted a systematic review and meta-analysis of
individual participant data to examine the efficacy of adding STPP to
antidepressants in the treatment of depression. We aimed to examine
two types of comparisons: 1) combined treatment of antidepressants
and STPP versus antidepressant mono-therapy, and 2) combined
treatment of antidepressants and STPP versus combined treatment of
antidepressants and brief supportive psychotherapy. The first compar-
ison relates to the overall additional benefits of STPP added to anti-
depressants in terms of both specific and non-specific treatment effects.
Assuming that the efficacy of brief supportive psychotherapy is mainly
determined by non-specific treatment factors as being empathically
understood by a therapist or general advises how to deal with depres-
sive symptoms, the second contrast relates to the specific treatment
effects of STPP. We aimed to examine the efficacy of adding STPP to




This study is part of a large systematic review and individual par-
ticipant data meta-analysis project that aims to examine different as-
pects of STPP for depression efficacy and that was registered in the
PROSPERO International prospective register of systematic reviews
(registration number: CRD42017056029). The study protocol of this
project was published too (Driessen et al., 2018).
2.2. Search strategy
We used an extensive search strategy including six different search
methods in order to retrieve as many relevant studies as possible. First,
we systematically searched the bibliographic databases PubMed,
PsycINFO (via EBSCO), Embase.com, Web of Science (via Elsevier), and
Cochrane's Central Register of Controlled Trials (via Wiley). Search
terms included a wide range of synonyms, both in index terms and free-
text words, for 1) psychodynamic psychotherapy (e.g., psychotherapy,
psychoanalytic), 2) therapy (e.g., psychotherapy), 3) psychodynamic
(e.g., dynamic*), and 4) depression (e.g., depressive disorder). These
four sets of search terms were combined as follows: (#1 OR (#2 AND
#3)) AND #4. The exact terms for the search in PubMed are provided in
the study protocol (Driessen et al., 2018; Table 1). Complete search
terms for all electronic databases are available on request from the
corresponding author. No language or date restrictions were applied in
the searches.
Second, in order to identify relevant studies from the so-called ‘grey
literature’ produced by organizations outside of the traditional aca-
demic publishing and distribution channels, we searched GLIN, a Dutch
electronic database for grey literature, and UMI database ProQuest for
digital dissertations. Third, a prospective trial register was searched for
unpublished ongoing research (http://www.controlled-trials.com). The
grey literature and prospective trial register searches were conducted
using the search strategy described above. Fourth, we searched an
Internet database of controlled and comparative outcome studies on
psychological treatments of depression (http://www.
psychotherapyrcts.org) for studies examining STPP. Fifth, reviews and
meta-analyses concerning the efficacy of psychodynamic treatments for
depression or for psychiatric disorders in general retrieved from the
first search method were screened for relevant references not located by
means of the other search methods. Sixth, we contacted an email list of
researchers in the field of psychodynamic therapy to ask for ongoing or
unpublished studies. Literature searches were performed according to
this strategy in 2007 and 2014 for two previous conventional meta-
analyses concerning the efficacy of STPP for depression (Driessen et al.,
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2010, 2015) and were updated June 19th, 2017 for this study using the
same search strategy.
To make sure that we did not miss any studies published after the
June 19th, 2017 literature search update, we searched an existing da-
tabase of randomized clinical trials examining the efficacy of psycho-
logical treatments for depression that has been described in detail
elsewhere (Cuijpers, van Straten, Warmerdam, & Andersson, 2008) and
that has been used in a series of published meta-analyses (www.
evidencebasedpsychotherapies.org). This database is annually updated
through comprehensive literature searches in the bibliographic data-
bases PubMed, PsycINFO, Embase.com, and the Cochrane Library. The
search strings use a combination of index terms and free-text words for
psychological treatments and depression. We searched this database for
additional studies meeting the inclusion criteria for this review pub-
lished between January 1st, 2017 and January 1st, 2020.
2.3. Selection of studies
We included studies if they reported (a) outcomes on standardized
measures of (b) depressed (c) adult participants (d) receiving STPP.
Participants were considered depressed if they met specified criteria for
major depressive disorder or another unipolar mood disorder as as-
sessed by means of a semi-structured interview or clinicians' assess-
ment, or if they presented an elevated score above the ‘no depression’
cut-off on a standardized measure of depression. Participants needed to
be at least 18 years old, and studies concerning older adults (mean
age > 55) were included as well. We included studies in which STPP
(a) was based on psychoanalytic theories and practices, (b) was time-
limited from the onset (i.e., not a therapy that was brief only in retro-
spect), and (c) applied verbal techniques (e.g., therapies applying art as
expression form were not considered STPP). Studies needed to include
at least 10 participants.
The screening process consisted of three phases. At first, the selec-
tion criteria were applied to the citations generated from the searches
independently by two raters. Disagreements were discussed and re-
solved by consensus. Unless they could be definitely excluded, titles
identified as potentially relevant were requested in full text. During the
second screening phase, two independent raters applied the selection
criteria to the full-text papers. Disagreements were discussed and re-
solved by consensus. During the third phase, two expert STPP re-
searcher-clinicians checked that the therapies described were psycho-
dynamic in nature to make sure that the treatments examined were
actual STPPs. Again, disagreements were discussed and resolved by
consensus. When disagreements could not be resolved in this way, a
third rater was consulted. From the resulting set of studies, we finally
identified randomized comparisons of combined treatment of anti-
depressants and STPP versus antidepressant mono-therapy or versus
antidepressants and brief supportive psychotherapy, provided in-
dividually in an outpatient setting.
2.4. Data collection
Next, authors of the included studies were contacted and invited to
contribute the participant-level data of their studies. Researchers who
shared their data were offered co-authorship for publications based on
their study's data, given that they would meet standard criteria for
authorship of scientific publications according to internationally ac-
cepted criteria (www.icmje.org). In addition, researchers who shared
their data were offered use of the collective database to examine other
research questions provided that the primary investigators of the ori-
ginal trials approved the use of their data for this purpose.
Contact details of all first authors were collected from the relevant
publications, or if not reported there, through Internet searches or
personal contacts with other researchers. First authors were then con-
tacted by email with a letter of invitation outlining the project's goals
and asking if they would be willing to collaborate by sharing the
participant-level data of their trial. If an author did not respond after
three weeks, a second and third email were sent. In case of non-re-
sponse to email, a letter was sent (again with three attempts). If still no
response was received, we tried to contact the author by telephone. If
all these attempts failed, the last, second, third, fourth, etc. author of
the study (in this order) were contacted in the same way. If none of the
authors responded to these efforts, other ways were sought to contact
one of the authors (e.g., via colleagues or anyone who might know
them). Study data were considered unavailable only if all these at-
tempts failed, or in the event that an author indicated that the parti-
cipant-level data had not been retained or declined sharing these data.
If the author was willing and able to share the individual participant
data of his/her trial, the author transferred the anonymized participant-
level dataset, including all outcome variables assessed during and after
treatment, both in the combined antidepressants and STPP condition as
well as in the comparison condition included in the study.
2.5. Data integrity check
After transfer of the dataset, the file was checked to examine whe-
ther the data received matched the data reported in the publication. For
both treatment conditions included in the study, sample size, number of
females, mean age, observed mean pre-treatment depression scores,
observed mean post-treatment score for the primary depression out-
come and the number of missing cases for the latter were calculated
from the dataset received and checked against the published article for
this purpose. Discrepancies were resolved with the authors. In addition,
the data were checked for invalid, out-of-range, or inconsistent items.
Furthermore, we checked the integrity of the randomization by in-
specting baseline differences in depression severity across treatment
arms.
For each study, we then listed all outcome variables, intermediate,
and follow-up assessments. We also extracted multiple study design
characteristics (e.g., target group, depression inclusion criteria) and
treatment characteristics (e.g., STPP model, antidepressant type), as
well as three STPP quality criteria (therapist training, use of a treatment
manual, and verification of treatment integrity). In addition, we ex-
tracted study validity criteria according to the Cochrane risk of bias
assessment tool (Higgins, Altman, & Sterne, 2011) for random sequence
generation (selection bias), allocation concealment (selection bias),
blinding of outcome assessment (detection bias), and incomplete out-
come data (attrition bias). Blinding of participants and personnel
(performance bias) was not rated, as it is considered not possible to
blind participants and therapists to treatment in psychotherapy re-
search. Selective reporting (reporting bias) was also not rated. This was
considered not applicable, as the authors shared their datasets in-
cluding all outcome measures assessed.
After checking the data, the datasets were standardized. For this
purpose, a copy of each trial's raw data file was recoded into a data file
that matched the individual participant data meta-analysis database in
terms of variables. Next, the individual study data files were con-
catenated in one database structured by study and individual partici-
pant ID. After all data files were recoded and entered, the data for each
study was checked against the original data file received for accuracy.
2.6. Outcome measures
The primary outcome for this study was treatment efficacy as as-
sessed by a continuous depression outcome measure at post-treatment.
The secondary outcome was treatment efficacy as assessed by a con-
tinuous depression outcome measure at follow-up. For each trial, we
identified the primary continuous depression outcome as defined by the
study authors. All instruments explicitly measuring depression qualified
in this regard. Because different depression measures were used, we
standardized the depression outcomes by converting the depression
scores into z-scores within each study. Sensitivity analyses were
E. Driessen, et al. Clinical Psychology Review 80 (2020) 101886
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conducted using unstandardized scores for each depression measure
that was assessed in the majority of studies included in the meta-ana-
lysis.
2.7. Data-analysis
We conducted individual participant data meta-analyses according
to the one-stage approach, because that provides a more exact like-
lihood in the case of small studies (Burke, Ensor, & Riley, 2017). We
conducted individual participant data meta-analyses using mixed
model analyses with a three-level structure (study, participant, repeated
measures) to take into account between-study heterogeneity. A re-
stricted maximum likelihood estimation was used, because this is re-
commended when there are few studies in the meta-analysis or studies
have small sample sizes (Higgins, Whitehead, Turner, Omar, &
Thompson, 2001). The analyses were based on the intent-to-treat
samples, including all participants randomized.
We started with a basic model including a main effect for time and a
time-by-treatment interaction. This approach is recommended by Twisk
et al. (2018), because it adequately accounts for baseline values of
depression and because of its favorable properties with regard to
missing data (i.e., participants with only a baseline value but missing
post-treatment and follow-up assessments are still included in the
analyses). Time was treated as a categorical variable, to facilitate the
assessment of treatment effects at the different time points. The basic
model had a random intercept and fixed slopes. We examined whether
adding a random slope to the time-by-treatment interaction resulted in
a model improvement. If this was the case, the model that included a
random slope was used for effect estimation.
Using this approach, treatment effects can be directly obtained from
the regression coefficients of the time-by-treatment interactions (Twisk
et al., 2018). The regression coefficients of the time-by-treatment in-
teractions at post-treatment and follow-up represent the treatment
comparisons at these assessment moments and can be interpreted as
Cohen's d effect sizes for analyses with z-scores as outcome measure and
as point differences for analyses with unstandardized scores as outcome
Records idenfied through  
database searching 























Addional records idenfied through 
other sources 
(n = 147) 
Records a!er duplicates removed 
(n = 3641) 
Records screened 
(n = 3641) 
Records excluded 
(n = 3233) 
Full-text arcles assessed for 
eligibility 
(n = 408) 
Full-text arcles excluded (n = 395)  
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- Review/meta-analysis (n = 20);  
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literature search update  
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Studies included in meta-
analysis 
(n = 7) 
Total number of included 
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 (n = 7) 
Records excluded (n = 13) 
- Other treatment comparison (n = 13) 
Fig. 1. PRISMA flow diagram of literature search update.
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measure. For the analyses of post-treatment outcomes, we excluded
follow-up data in which additional help-seeking could not be con-
trolled. We assessed heterogeneity with the I2 statistic, which describes
the variance between studies as a proportion of the total variance.
We visually inspected histograms of residuals and standardized re-
siduals to address the assumption of normally distributed data. To ex-
amine the impact of risk of bias, we added the risk of bias items as
dichotomous covariates to the mixed model analyses (Higgins,
Thompson, & Spiegelhalter, 2009). Furthermore, we conducted sensi-
tivity analyses including only studies that scored negative on all four
risk of bias criteria assessed. Similarly, we examined the impact of STPP
quality by adding these items as dichotomous covariates to the mixed
model analyses and by conducting sensitivity analyses that only in-
cluded studies scoring positive on all three STPP quality criteria as-
sessed. Finally, we conducted sensitivity analyses only including those
studies that enrolled participants meeting diagnostic criteria for de-
pression (rather than presenting an elevated score on a standardized




For detailed results of the 2007 and 2014 literature searches, we
refer the reader to Driessen et al. (2010, 2015). These searches identi-
fied 7 randomized comparisons of combined treatment of anti-
depressants and STPP versus antidepressants with or without brief
supportive psychotherapy (Burnand, Andreoli, Kolatte, Venturini, &
Rosset, 2002; de Jonghe, Kool, van Aalst, Dekker, & Peen, 2001; Lopez
Rodriguez, Lopez Butron, Vargas Terrez, & Villamil Salcedo, 2004;
Maina, Rosso, Crespi, & Bogetto, 2007; Maina, Rosso, Rigardetto,
Chiadò Piat, & Bogetto, 2010; Martini, Rosso, Chiodelli, De Cori, &
Maina, 2011; Vitriol, Ballesteros, Florenzano, Weil, & Benadorf, 2009).
Results of the literature search update that was performed June 19th,
2017 using the same search strategy are presented in Fig. 1. After re-
moving duplicates, this literature search update resulted in 3641 re-
cords, of which the majority (3233) was excluded in the first screening
phase. A total of 408 titles were reviewed in full-text. Of these, none
met the inclusion criteria for the present review. Finally, the database
included 166 randomized clinical trials examining the efficacy of psy-
chological treatments for depression published between January 1st,
2017 and January 1st, 2020. These were all reviewed in full-text, but
none were identified as randomized comparisons of combined treat-
ment of antidepressants and STPP versus antidepressants with or
without brief supportive psychotherapy.
Thus, 7 studies met the inclusion criteria for the present review.
Individual participant data were obtained for all these 7 studies
(100.0%). The characteristics of the 7 included studies are described in
Table 1. Three (42.9%) studies compared combined treatment of anti-
depressants and STPP with antidepressant mono-therapy, while the
other four studies (57.1%) compared combined treatment of anti-
depressants and STPP with combined treatment of antidepressants and
brief supportive psychotherapy. In all studies, participants were re-
cruited from clinical samples (who actively sought help for depression
first and were then asked to participate in the study). Depression in-
clusion criteria typically consisted of a DSM or ICD-10 depression di-
agnosis combined with an elevated HAMD score, though in one study
an elevated HAMD score constituted the sole inclusion criterion for
depression. In four studies (57.1%), the target group was adults with
depression in general, while three studies (42.9%) included participants
with specific anxiety disorder comorbidities. The study samples ranged
from 20 to 167 participants. Follow-up assessments were conducted in
6 (85.7%) studies, with follow-up periods ranging from 6 months to
1 year post-baseline. All studies used the HAMD as primary outcome
measure, with 6 (85.7%) studies assessing the 17-item version and 1
(14.3%) study assessing the 21-item version.
STPP was based on the principles described by Safran and Muran
(2000), Andreoli (1999), de Jonghe, Rijnierse, and Janssen (1994),
Bellak (1993, 1994), Malan (1963, 1976), and Vitriol (2005). Treat-
ment periods ranged from 10 to 26 weeks. Antidepressants included
various selective serotonin reuptake inhibitors, though one study fo-
cused on a tricyclic antidepressant. In terms of the STPP quality criteria,
therapists were adequately trained and treatment integrity was verified
in all of the included studies. STPP was conducted according to a
treatment manual in all but one study (85.7%; Lopez Rodriguez et al.,
2004).
The 7 included studies totaled 482 participants, 238 (49.4%) in the
combined antidepressants and STPP treatment conditions and 244
(50.6%) in the comparison conditions. The majority of the participants
(70.0%) was female, with a mean age of 35.3 (SD = 9.9) years. The
mean baseline 17-item HAMD score was 22.9 (SD = 7.9), indicating
moderate symptom levels.
An overview of the risk of bias assessment is provided in Table 2. As
can be seen in this table, all studies employed adequate random se-
quence generation and allocation concealment procedures. However,
outcome assessors were not blind to treatment condition in two studies
(28.6%) and for one other study (14.3%) the complete intent-to-treat
data were not retained. Four studies (57.1%) scored negative on all four
risk of bias criteria assessed.
3.2. Efficacy outcomes
Regression coefficients of the time-by-treatment interactions are
reported in Table 3 for each of the included studies and in Table 4 for all
meta-analyses. Across the total sample of 7 studies, combined treatment
of antidepressants and STPP was found to be significantly more effi-
cacious than antidepressants with/without brief supportive
Table 2
Risk of bias assessment of the included studies.
Study Selection bias Detection bias Attrition bias
Random sequence generation Allocation concealment Blinding of HAMD assessment Incomplete outcome data
Antidepressants+ STPP versus antidepressant mono-therapy
de Jonghe et al., 2001 + + + +
Lopez Rodriguez et al., 2004 + + + −
Maina et al., 2010 + + + +
Antidepressants+ STPP versus antidepressants+ brief supportive psychotherapy
Burnand et al., 2002 + + − +
Maina et al., 2007 + + + +
Martini et al., 2011 + + + +
Vitriol et al., 2009 + + − +
Note. HAMD=Hamilton Depression Rating Scale; STPP= short-term psychodynamic psychotherapy.
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psychotherapy with a Cohen's d effect size of 0.26 (SE = 0.10; p= .01)
at post-treatment. In the 6 studies that assessed the 17-item HAMD, a
non-significant 1.6 (SE = 1.3; p= .21) HAMD point difference favoring
combined treatment of antidepressants and STPP was found at post-
treatment. At follow-up, combined treatment of antidepressants and
STPP was again significantly more efficacious than antidepressants
with/without brief supportive psychotherapy, though effects were
larger with a Cohen's d effect size of 0.50 (SE = 0.10; p < .001) and a
3.7 (SE = 1.3; p= .01) HAMD point difference. Heterogeneity was low
to moderate in these analyses (I2 = 0.0–45.7%).
A similar pattern of findings was observed in the subset of 4 (57.1%)
studies contrasting combined treatment of antidepressants and STPP
with combined treatment of antidepressants and brief supportive
psychotherapy, with a significant effect size of d = 0.26 (SE = 0.13;
p = .04) and a non-significant 1.6 (SE = 1.5; p = .30) HAMD point
difference at post-treatment, and with a significant effect size of
d = 0.82 (SE = 0.15; p < .001) and a significant 6.2 (SE = 1.1
p < .001) HAMD point difference at follow-up. Heterogeneity was low
to moderate in these analyses (I2 = 0.0–53.9%).
In the subset of 3 (42.9%) studies that compared combined treat-
ment of antidepressants and STPP to antidepressant mono-therapy, no
statistically significant time-by-treatment interactions were observed in
the analyses with HAMD z-scores as outcome measure (post-treatment:
Cohen's d = 0.24, SE = 0.15, p = .11; follow-up: Cohen's d = 0.21,
SE = 0.13; p = .11), while combined treatment was found to be sig-
nificantly more efficacious than antidepressant mono-therapy in the
analyses with unstandardized 17-item HAMD scores as outcome mea-
sure. In these latter analyses, HAMD point differences at post-treatment
and follow-up were 2.5 (SE = 0.9; p = .01) and 2.4 (SE = 0.9;
p = .01), respectively. Heterogeneity was low in these analyses
(I2 = 0.0–3.1%).
3.3. Sensitivity analyses
Adding blinding of HAMD assessment and incomplete outcome data
as covariates to the analyses including all studies resulted in a similar
pattern of findings (Table 4), with a significant effect size of d = 0.26
(SE = 0.10; p = .01) and a non-significant 1.7 (SE = 1.3; p = .20)
HAMD point difference at post-treatment, and with a significant effect
size of d= 0.50 (SE = 0.10; p < .001) and a significant 3.3 (SE = 1.4
p= .02) HAMD point difference at follow-up. Repeating the analyses in
the subset of 4 (57.1%) studies that scored negative on all 4 risk of bias
criteria assessed resulted in somewhat smaller effects, with a non-sig-
nificant effect size of d = 0.11 (SE = 0.12; p = .38) and a significant
1.5 (SE = 0.7; p = .04) HAMD point difference at post-treatment, and
with a significant effect size of d= 0.42 (SE = 0.11; p < .001) and a
significant 2.9 (SE = 1.4; p= .04) HAMD point difference at follow-up.
Table 3
Cohen's d effect sizes of adding STPP to antidepressants at post-treatment and
follow-up in each of the included studies.
Study Post-treatment Follow-up
d SE p d SE p
Antidepressants+ STPP versus antidepressant mono-therapy
de Jonghe et al., 2001 −0.289 0.202 0.153 −0.221 0.185 0.232
Lopez Rodriguez et al.,
2004
−0.488 0.446 0.274 −0.780 0.436 0.074
Maina et al., 2010 −0.036 0.235 0.878 0.043 0.202 0.831
Antidepressants+ STPP versus antidepressants+ brief supportive psychotherapy
Burnand et al., 2002 −0.109 0.232 0.638
Maina et al., 2007 0.151 0.356 0.671 −1.427 0.299 < 0.001
Martini et al., 2011 0.068 0.237 0.774 −0.681 0.262 0.009
Vitriol et al., 2009 −0.638 0.206 0.002 −0.659 0.215 0.002
Note. p= p-value; SE= standard error; STPP= short-term psychodynamic
psychotherapy. Negative signs indicate lower depressive symptom levels in the
combined antidepressants and STPP treatment condition than in the compar-
ison condition.
Table 4
Treatment effects of adding STPP to antidepressants at post-treatment and follow-up.
Outcome Post-treatment Follow-up
B SE p I2 B SE p I2
Main analyses
All studies
HAMD z-score (Cohen's d) −0.255 0.096 0.008 0.00 −0.503 0.102 <0.001 0.00
17-item HAMD score −1.630 1.295 0.208 45.72 −3.674 1.341 0.006 38.70
Antidepressants+ STPP versus antidepressant mono-therapy
HAMD z-score (Cohen's d) −0.237 0.146 0.105 0.00 −0.211 0.133 0.113 0.00
17-item HAMD score −2.524 0.921 0.006 0.00 −2.415 0.931 0.009 3.06
Antidepressants+ STPP versus antidepressants+ brief supportive psychotherapy
HAMD z-score (Cohen's d) −0.262 0.127 0.039 0.00 −0.823 0.153 <0.001 0.00
17-item HAMD score −1.550 1.509 0.304 53.90 −6.215 1.100 <0.001 47.67
Sensitivity analyses
All studies – risk of bias items added as covariates
HAMD z-score (Cohen's d) −0.255 0.096 0.008 0.00 −0.503 0.102 <0.001 0.00
17-item HAMD score −1.668 1.303 0.201 30.38 −3.327 1.427 0.020 25.52
Low risk of bias studies only
HAMD z-score (Cohen's d) −0.108 0.122 0.376 0.00 −0.424 0.114 <0.001 0.00
17-item HAMD score −1.509 0.723 0.037 18.67 −2.916 1.445 0.044 15.37
All studies – STPP quality items added as covariates
HAMD z-score (Cohen's d) −0.255 0.096 0.008 0.00 −0.503 0.102 <0.001 0.00
17-item HAMD score −1.630 1.295 0.208 45.72 −3.674 1.341 0.006 38.70
High STPP quality studies only
HAMD z-score (Cohen's d) −0.247 0.098 0.012 0.00 −0.492 0.104 <0.001 0.00
17-item HAMD score −1.630 1.295 0.208 45.72 −3.674 1.341 0.006 38.70
Studies including participants with diagnosed mood disorders only
HAMD z-score (Cohen's d) −0.289 0.102 0.005 0.00 −0.480 0.109 <0.001 0.00
17-item HAMD score −2.104 1.311 0.109 40.24 −3.780 1.755 0.031 39.29
Note. B= regression coefficient; HAMD=Hamilton Depression Rating Scale; p=p-value; SE= standard error; STPP= short-term psychodynamic psychotherapy.
Negative signs indicate lower depressive symptom levels in the combined antidepressants and STPP treatment condition than in the comparison condition. Numbers
printed in bold indicate a statistically significant time-by-treatment interaction (p < .05).
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Heterogeneity was low in all these analyses (I2 = 0.0–30.4%).
Adding use of a treatment manual as a covariate to the analyses
including all studies did not change the pattern of results, nor did re-
peating the analyses in the subset of 6 (85.7%) studies that scored
positive on all 3 STPP quality criteria assessed (Table 4). Repeating the
analyses in the subset of 6 (85.7%) studies that only included partici-
pants meeting diagnostic criteria for depression also did not change the
pattern of results (Table 4).
4. Discussion
4.1. Findings
We conducted a systematic review and meta-analysis of individual
participant data to examine the efficacy of adding STPP to anti-
depressants in the treatment of depression. Across the total sample of
seven studies that were identified by a thorough literature search,
combined treatment of antidepressants and STPP was found to be sig-
nificantly more efficacious than antidepressants with/without brief
supportive psychotherapy. The size of this effect was small at post-
treatment and moderate at follow-up. These results are in line with
previous reviews suggesting increased treatment efficacy when adding
psychotherapy in general (Cuijpers et al., 2014; Karyotaki et al., 2016)
as well as STPP specifically (Fonagy, 2015) to antidepressant medica-
tion.
The overall findings appeared to be mostly driven by the subset of
studies that contrasted combined treatment of antidepressants and
STPP with combined treatment of antidepressants and brief supportive
psychotherapy. Assuming that the efficacy of brief supportive psy-
chotherapy is mainly determined by non-specific treatment factors as
being empathically understood by a therapist or general advises how to
deal with depressive symptoms, this contrast relates to STPP's specific
treatment effects. In this set of studies, combined treatment of anti-
depressants and STPP was found to be significantly more efficacious
than combined treatment of antidepressants and brief supportive psy-
chotherapy with a small effect size at post-treatment and a large effect
size at follow-up.
The effect of adding STPP to antidepressants at follow-up was less
apparent in the set of studies that contrasted combined treatment of
antidepressants and STPP with antidepressant mono-therapy. In this
subset of studies, small effects were found at both post-treatment and
follow-up that were significantly superior to antidepressant mono-
therapy when using unstandardized 17-item HAMD scores as outcome
measure, but not when using HAMD z-scores as outcome measure. We
think that this effect difference at follow-up is the consequence of the
different studies that constitute the two subsets. For example, one of the
studies comparing combined treatment of antidepressants and STPP
versus antidepressant mono-therapy found no effect of adding STPP at
both post-treatment (d = −0.04, SE = 0.24, p = .88) and follow-up
(d = 0.04, SE = 0.20, p= .83; Maina et al., 2010). This study focused
on comorbid major depression and obsessive-compulsive disorder and
concluded that supplemental STPP has no significant clinical effect on
such patients who are receiving adequate medications.
4.2. Strengths and limitations
This study has a number of strengths. First, individual participant
data were obtained for all included studies. Thus, this meta-analysis did
not suffer from data availability bias. Similarly, selection bias appeared
to be limited as all studies employed adequate sequence generation and
allocation concealment procedures. Second, by using individual parti-
cipant data meta-analytic methods, we were able to improve the quality
of the data and the analyses when compared to conventional meta-
analysis methods. For instance, we worked with intent-to-treat samples
that were not always reported on in the original study publications, and
we facilitated standardization across studies by using the same
statistical method for data-analysis, appropriately adjusting for baseline
levels of depression in all studies (Twisk et al., 2018). Third, the in-
cluded studies shared similarities in terms of sample recruitment, de-
pression inclusion criteria, treatment format, and primary outcome
measure.
However, this study also has a number of limitations. First, even
though individual participant data could be obtained for all studies, the
total number of participants included in this meta-analysis is modest
(n= 482). Relatively few studies examined the efficacy of adding STPP
to antidepressants. We think this reflects that psychodynamic therapy
in general has been studied less extensively than other forms of psy-
chotherapy for depression, such as cognitive behavioural therapy (CBT;
e.g., Cuijpers et al., 2014). Second, and related, we cannot rule out the
possibility that we have missed additional studies meeting the inclusion
criteria, although we have tried to minimize this possibility by using an
extensive search strategy and we were able to include a study that did
not report the requisite data for effect size calculation in its publication
and was therefore excluded from previous conventional meta-analyses
(Driessen et al., 2010, 2015). Third, not all studies were free from de-
tection bias and attrition bias. However, effects were still apparent in
the sensitivity analyses that controlled for risk of bias in the primary
studies. Fourth, although the studies shared similarities, they also dif-
fered, for instance, with regard to the STPP model used, the type of
antidepressant examined, length of follow-up, and their focus on spe-
cific comorbidities. Therefore, this meta-analysis' results might not
generalize to all STPP modes, antidepressant types, and participant
groups. Fifth, this meta-analysis used depression level as the sole out-
come measure. Although depression symptom level was specified a
priori as the primary outcome measure (Driessen et al., 2018), ex-
amining additional outcome measures (e.g., anxiety, interpersonal
functioning, quality of life) would have been desirable as these are
important aspects of participant functioning too. In addition, examining
cost-effectiveness would have been desirable as well to investigate
whether the benefits in terms of efficacy outweigh the costs of adding
STPP to antidepressant medication. However, this was not possible as
outcome measures other than depression were not assessed consistently
across the trials.
4.3. Clinical and research implications
The findings of this study suggest that people suffering from de-
pression and their clinicians might expect lower depressive symptom
levels when adding STPP to antidepressant medication. These benefits
might be small at post-treatment and the largest benefits might be ex-
pected at follow-up. The finding that these benefits might be related to
STPP's specific treatments effects as opposed to non-specific treatment
factors, implicate the need for proper therapist training and supervision
in order to capitalize on these specific STPP treatment effects.
Collectively, these findings add to the evidence-base of adding STPP to
antidepressants in the treatment of depression.
However, the findings of this study cannot be taken to imply that
combined treatment of antidepressants and STPP should be considered
the first choice treatment for individuals with depression, as this study
does not speak to comparative efficacy with other depression treat-
ments. Examining the relative merits of STPP versus other psy-
chotherapies as added to antidepressants requires randomized com-
parisons of combined treatment of antidepressants and STPP versus
combined treatment of antidepressants and another psychotherapy. The
literature searches for our larger STPP for depression individual parti-
cipant data meta-analysis project identified only one such study. This
was a pilot study comparing combined treatment of antidepressants and
STPP versus combined treatment of antidepressants and CBT, which
pooled the two treatment conditions in its report because of the small
sample size (n = 12; Perry, Banon, & Bond, 2020). One other study
compared STPP and CBT as mono-therapies, but offered additional
treatment with antidepressants to severely depressed participants
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(n = 129; Driessen et al., 2013). No significant treatment differences
were found in this subgroup of severely depressed participants re-
ceiving combined treatment (post-treatment: Cohen's d = 0.21, 95%
CI = −0.23 to 0.64, follow-up: d = 0.32, 95% CI = −0.15 to 0.79),
but favored combined treatment with CBT and were large enough to be
significant if replicated in a larger sample.
Considering the limitations of this study mentioned previously and
the clinical importance of the research question, the field would benefit
from further study of the efficacy of adding STPP to antidepressants in
the treatment of depression. In our opinion, comparisons of combined
treatment of antidepressants and STPP versus combined treatment of
antidepressants and brief supportive psychotherapy are most relevant
in this regard as they relate to STPP's specific treatment effects.
Comparisons of combined treatment of antidepressants and STPP versus
combined treatment of antidepressants and other psychotherapies (e.g.,
CBT) are also needed. Preferably, future study constitutes large-scale
rigorously conducted randomized clinical trials that also assess out-
come measures other than depression, including measures that facil-
itate cost-effectiveness analyses. As STPP might not be available for all
people with depression due to scarcity of treatment resources and be-
cause the addition of psychotherapy to antidepressant medication re-
quires a financial investment, future research examining which parti-
cipants benefit specifically from adding STPP to antidepressants in the
treatment of depression is also needed.
5. Conclusion
We examined the efficacy of adding STPP to antidepressants in the
treatment of depression by means of a systematic review and meta-
analysis of individual participant data, which is currently considered
the most reliable method for evidence synthesis. Across the total sample
of seven studies that were identified by a thorough systematic literature
search, adding STPP to antidepressants was found to be significantly
more efficacious than antidepressants with/without brief supportive
psychotherapy in terms of depressive symptom level at both post-
treatment and follow-up. Effects were most apparent at follow-up and
in studies that assessed STPP's specific treatment effects by including
brief supportive psychotherapy in the comparison condition. Effects
were still apparent in analyses that controlled for risk of bias and STPP
quality in the primary studies. Although further study is needed, par-
ticularly assessing cost-effectiveness and outcome measures other than
depression, these findings support the evidence-base of adding STPP to
antidepressants in the treatment of depression.
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